{"entity":{"id":"rarb","kind":"target","name":"RARB","aka":["retinoic acid receptor beta","Retinoic acid receptor beta","NR1B2","RRB2","RARbeta","RAR-beta"],"tldr":"RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.","summary":"Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, animal model 0.65, genetic association 0.00, clinical 0.97).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9865","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9865"},{"label":"UniProt P10826","url":"https://www.uniprot.org/uniprotkb/P10826/entry"},{"label":"NCBI Gene 5915","url":"https://www.ncbi.nlm.nih.gov/gene/5915"},{"label":"Ensembl ENSG00000077092","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000077092"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["leukaemia","myeloproliferative-neoplasms","aml","apl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"RARB","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9865","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9865","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P10826","url":"https://www.uniprot.org/uniprotkb/P10826/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000077092","url":"https://platform.opentargets.org/target/ENSG00000077092/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.60, myeloproliferative neoplasm 0.60, leukaemia 0.60, acute promyelocytic leukaemia 0.59 (GraphQL API, CC0)"}],"hgnc":"HGNC:9865","ensembl":"ENSG00000077092","uniprot":"P10826","entrez":"5915","biology":"Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Location: Nucleus; Cytoplasm (UniProt). Locus 3p24.2 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076)","Acute myeloid leukaemia: Open Targets association 0.60 with acute myeloid leukaemia (MONDO_0018874)","Acute promyelocytic leukaemia: Open Targets association 0.59 with acute promyelocytic leukaemia (MONDO_0012883)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/rarb/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}]}}